People · Operator
Named in public records as an officer, director or promoter · active 2024–2024 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| NGM Bio Holdings, Inc. | — | Biotechnology | Series C | $73.2M | $650.5M | 2024 |
Kara D. Calhoun at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kara D. Calhoun on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| William J. Rieflin | 1 | 4 |
| Shelly D. Guyer | 1 | 3 |
| Roger M Perlmutter | 1 | 3 |
| Hsiao D. Lieu | 1 | 2 |
| Diana Peng Bockus | 1 | 1 |
| Tim Peng Kutzkey | 1 | 1 |
| Peter M. Svennilson | 1 | 1 |
| David J. Goeddel | 1 | 1 |
| David J. Woodhouse | 1 | 1 |
| Daniel M. Kaplan | 1 | 1 |
| Valerie D. Pierce | 1 | 1 |
| Carole M. Ho | 1 | 1 |
| Jean-Frederic M. Viret | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.